Assessment of Efficacy of Combined Pharmacotherapy With Fixed Perindopril/Amlodipine Combination in Patients With Combined Cardiovascular Pathology in Outpatient Practice

Aim: to study effects of using fixed perindopril/amlodipine combination in complex treatment of patients with combined cardiac pathology in active observation mode, in comparison with other angiotensin converting enzyme (ACE inhibitors) or angiotensin II receptor antagonists (ARA), including free combination with calcium channel blockers (CCB) in conditions of routine outpatient practice. Materials and methods. The design of the study included two stages: I - monitoring effectiveness of pharmacotherapy performed in routine outpatient practice (duration of 2 months), II - “active treatment (management)” - changing the pharmacotherapy scheme in patients who did not reach the target level of “office” blood pressure (BP), monitoring patients for 6 months and carrying out, if necessary, dose correction of the newly appointed treatment regimen. The study included 50 patients aged 45-65 years with combined cardiovascular pathology: II-III degree arterial hypertension, I-III functional class (FC) stable angina pectoris, I-III FC chronic cardiac failure. Results. Number of patients who reached target level of office BP by the end of active observation was 41 (p<0.001 in comparison with routine therapy). During 6-month treatment episodes of ischemic ST-segment depression were eliminated in 37 patients (there were no such patients during routine therapy, p<0.001). At the end of the period of routine pharmacotherapy, 1 and 5 patients had a reduction (more than by 80% from the baseline level) of the number of ventricular and supraventricular extrasystoles, respectively. During 6-month active treatment extrasystoles were additionally eliminated in 14 (p<0.001) and 18 (p<0.010) patients, respectively. During the period of active treatment there occurred significant improvement of parameters of role-physical functioning, vitality, mental health (p<0.05) compared with preceding period of 2 months of routine management. During routine pharmacotherapy, depression and anxiety were eliminated in 14 and 13 patients, respectively. During further active treatment parameters of depression and anxiety were normalized in 23 and 20 patients, respectively (p<0.05 for anxiety and p<0.01 for depression vs. preceding period of treatment in routine conditions). Conclusion. Replacement of free combinations of ACE inhibitors or ARA and CCB with fixed perindopril/ amlodipine combination in the complex pharmacotherapy of patients with combined cardiac pathology, together with adjustment of the entire management regimen in accordance with current clinical recommendations and the use of active observation of patients in comparison with preceding routine outpatient treatment was associated with significant positive effects on daily BP profile, ECG signs of myocardial ischemia and arrhythmic activity, parameters of quality of life, and levels of anxiety and depression

артериальная гипертония, стабильная стенокардия напряжения, хроническая сердечная недостаточность, фармакотерапия, arterial hypertension, stable angina pectoris, chronic heart failure, pharmacotherapy

1. Martsevich S. Y., Kutishenko N. P., Tolpygina S. N. et al. The efficacy and safety of drug therapy for primary and secondary prevention of cardiovascular diseases. Clinical recommendations. Journal Rational Pharmacotherapy in Cardiology 2011;5:5-72

2. Popova E. K., Arkhipova N. S., Tomsky M. I. Frequency of arterial hypertension in the group of patients with ischemic heart disease of elderly age living in the conditions of the extreme north. Sibirskii Med Journal 2015;1:73-76. Russian (Попова Е. К., Архипова Н. С., Томский М. И. Частота артериальной гипертензии в группе больных ишемической болезнью сердца пожилого возраста, проживающих в условиях Крайнего Севера. Сибирский медицинский журнал 2015;1:73-76).

3. Heidenreich P. A., Trogdon J. G., Khavjou O. A. et al. Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association. Circulation 2011;123:933-944.

4. Mareev V. Y., Ageev F. T., Arutyunov G. P. et al. Diagnosis and treatment of chronic heart failure 4th ed. National clinical guidelines.Journal of heart failure 2013;14:379-472. Russian (Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Диагностика и лечение хронической сердечной недостаточности (IV пересмотр). Национальные рекомендации. Журнал Сердечная Недостаточность 2013;14:379-472).

5. Diagnosis and treatment of chronic ischemic heart disease. Clinical recommendations developed on behalf of the Ministry of Health of the Russian Federation. Moscow. 2013; 51 p. Russian (Диагностика и лечение хронической ишемической болезни сердца. Клинические рекомендации, разработанные по поручению МЗ РФ. М. 2013; 51 с).

6. Diagnosis and treatment of hypertension. Clinical recommendations developed on behalf of the Ministry of Health of the Russian Federation. M. 2013; 63 p. Russian (Диагностика и лечение артериальной гипертензии. Клинические рекомендации, разработанные по поручению МЗ РФ. М. 2013; 63 с).

7. Parakhonsky A. P. Assessmen to the quality of life of patients with arterial hypertension. Fundamental research 2006;12:33-34. Russian (Парахонский А. П. Оценка качества жизни больных артериальной гипертонией. Фундаментальные исследования 2006;12:33-34).

8. Ostroumova O. D., Mamaev V. I., Abakumov Ju. E. et al. Influence of hypotensive therapy on quality of life. Kardiologija 2003;43 (3):99-102. Russian (Остроумова О. Д., Мамаев В. И., Абакумов Ю. Е. и др. Влияние гипотензивной терапии на качество жизни. Кардиология 2003;43 (3):99-102).

9. Glezer M. G., Vygodin V. A., Avakjan A. A., Prokof'eva E. B. ot litsa uchastnikov issledovaniya. Results of the Russian EXPERT Program (Post-marketing supervision over efficiency and influence of a preparation the equator on quality of life at patients with arterial hypertensions in out-patient practice). Kardiologiya 2014;54 (3): 15-22. Russian (Глезер М. Г., Выгодин В. А., Авакян А. А., Прокофьева Е. Б. от лица участников исследования. Результаты российской Программы ЭКСПЕРТ (Постмаркетинговое наблюдение за эффективностью и влиянием препарата экватор на качество жизни у пациентов с артериальной гипертонией в амбулаторной практике). Кардиология 2014;54 (3):15-22).

10. Rogoza A. N., Nikolsky V. P., Oschepkova E. V. et al. Daily monitoring ofblood pressure in hypertension. (Methodological issues). Russian Cardiology Research and Production Complex of the Ministry of Health of the Russian Federation. 37 p. www.bplab.ru. Russian (Рогоза А. Н., Никольский В. П., Ощепкова Е. В. и др. Суточное мониторирование артериального давления при гипертонии. (Методические вопросы). Российский кардиологический научно-производственный комплекс МЗ РФ. 37С. www.bplab.ru).

11. Tikhonenko V. M. Formation of the clinical conclusion according to holter monitoring. Manual for doctors. St. Petersburg: Meditsinskoe izdatel'stvo 2000; 24 p. Russian (Тихоненко В. М. Формирование клинического заключения по данным холтеровского мониторирования. Пособие для врачей. Санкт-Петербург: Медицинское издательство 2000; 24 с).

12. Novik A. A., Ionova T. I. The guide to research of quality of life in medicine. М.: OLMA. Media Grupp 2007; 315 р. Russian (Новик А. А., Ионова Т. И. Руководство по исследованию качества жизни в медицине. М.: ОЛМА. Медиа Групп 2007; 315 с).

13. Borovikov V. P., Borovikov I. P. STATISTICA. Statistical analysis and data processing in a Windows. Moscow: Filin. 1998; 608 p. Russian (Боровиков В. П., Боровиков И. П. STATISTICA. Статистический анализ и обработка данных в среде Windows. М.: Филинъ. 1998; 608 c).

14. Glantz S. Medico-biological statistics. M.: Practice. 1999; 429 p. Russian (Гланц С. Медико-биологическая статистика. М.: Практика. 1999; 429 с).

15. Dahlöf B., Sever P. S., Poulter N. R. et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre andomized controlled trial. Lancet 2005;366 (9489):895-906.

16. Karpov Yu. A., Gorbunov V. M., Deev A. D. The BREAK-2 trial: the effect of a fixed combination of perindopril/amlodipine on blood pressure measured in the physician's office, using daily monitoring and self-monitoring in patients with uncontrolled arterial hypertension. Atmosphere. Cardiology news 2014; ( 1 ) : 1-6. Russian (Карпов Ю. А., Горбунов В. М., Деев А. Д. от имени участников исследования ПРОРЫВ-2. Исследование ПРОРЫВ-2: влияние фиксированной комбинации периндо-прил/амлодипин на артериальное давление, измеренное в кабинете врача, с помощью суточного мониторирования и самоконтроля у пациентов с неконтролируемой артериальной гипертонией. Атмосфера. Новости кардиологии 2014; (1):1-6).

17. Karpov Yu. A., Deev A. D. On behalf of doctors participating in the PROPYV program. Uncontrolled arterial hypertension is a new opportunity to solve the problem of increasing the effectiveness of treatment. Cardiology 2012;2:29-35. Russian (Карпов Ю. А., Деев А. Д. от имени врачей - участников программы «ПРОРЫВ» Неконтролируемая артериальная гипертония - новые возможности в решении проблемы повышения эффективности лечения. Кардиология 2012;2:29-35.

18. Fox K. M. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-800.

19. Patel ADVANCE Collaborative Group. Effect of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007;370:829-840.

20. PROGRESS Collaborative Group. Randomised trial of a perindopril based blood-pressure lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 2001;358 (9287):1033-1041.

21. Lopatin Yu. M. Amlodipine in the treatment of patients with ischemic heart disease: focus on the antiatherosclerotic properties of the drug. Rational pharmacotherapy in cardiology 2010;6 (1):77-82. Russian (Лопатин Ю. М. Амлодипин в лечении больных ишемической болезнью сердца: фокус на антиатеросклеротические свойства препарата. Рациональная фармакотерапия в кардиологии 2010;6 (1):77-82).

22. Omvik P., Herland O. B, Thaulow E. et al. Evaluation and quality-of-life assessment of amlodipine and enalapril in patients with hypertension. J Hum Hypertens 1995;9 Suppl 1:17-24.

23. Bezuglova E. I., Luneva Yu. V., Filippenko N. G. et al. The state of psy-choemotional status and quality of life in patients with combined cardiovascular pathology in conditions of actual clinical practice. Kursk scientific-practical herald “The Man and His Health” 2013;4:55-57. Russian (Безуглова Е. И., Лунева Ю. В., Филиппенко Н. Г. и др. Состояние психоэмоционального статуса и качество жизни у больных с сочетанной сердечно-сосудистой патологией в условиях реальной клинической практики. Курский научно-практический вестник «Человек и его здоровье» 2013;4:55-57).